ストックスクリーナーアプリを入手
0.92
4.39%
0.0387
プレマーケット:
.94
0.02
+2.17%
前日終値:
$0.8813
開ける：
$0.8898
24時間の取引高:
4.84M
Relative Volume:
1.09
時価総額：
$174.30M
収益：
$116.33M
当期純損益:
$-209.25M
株価収益率:
-0.434
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
-3.16%
1か月 パフォーマンス:
-45.24%
6か月 パフォーマンス:
-56.19%
1年 パフォーマンス:
-53.77%
1日の値動き範囲:
$0.8519
$0.9389
1週間の範囲:
$0.8191
$1.06
52週間の値動き範囲:
$0.8191
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
0.92 | 174.30M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Esperion Reveals Next-Gen Cholesterol Treatment Strategy: FDA-Approved Non-Statin Leader Updates Growth Plans - Stock Titan
Esperion to Participate in The Citizens Life Sciences Conference - GlobeNewswire
Esperion unveils novel PSC treatment candidates By Investing.com - Investing.com Canada
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Esperion (ESPR) Advances ACLY Inhibitors for Rare Liver Disease Treatment | ESPR Stock News - GuruFocus
Esperion unveils novel PSC treatment candidates - Investing.com
Esperion Unveils Promising Research Supporting Lead - GlobeNewswire
New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity - Stock Titan
Esperion to Report First Quarter 2025 Financial Results on May 6 - The Manila Times
Esperion Q1 2025 Earnings Preview: What's Next for this FDA-Approved Cardiovascular Drug Maker? - Stock Titan
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Esperion stock hits 52-week low at $0.91 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $0.91 amid challenges - Investing.com
Esperion Therapeutics (ESPR) Faces Downward Earnings Estimate Re - GuruFocus
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 - The Manila Times
Esperion to Host R&D Day to Highlight Cardiometabolic - GlobeNewswire
Major Pipeline Expansion: Esperion to Reveal New Disease Target at R&D Day - Stock Titan
Esperion stock hits 52-week low at $1.17 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.17 amid challenges - Investing.com Australia
Esperion at Needham Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Esperion announces CCO Eric Warren to step down - Investing.com Australia
Esperion announces CCO Eric Warren to step down By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Appoints Robert E. Hoffman as New Director - TipRanks
Esperion appoints Robert Hoffman to board of directors - Investing.com
Esperion appoints Robert Hoffman to board of directors By Investing.com - Investing.com UK
Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire
Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan
Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan
BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia - The Manila Times
Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire
Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com
FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan
Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com India
Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa
Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com
Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India
Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
1.80%
大文字化:
|
ボリューム (24 時間):